LONDON--U.K. drugmaker GlaxoSmithKline PLC (GSK.LN) Monday
publicized positive results from a late-stage study of a treatment
for pulmonary arterial hypertension, a condition characterized by
constriction of the blood vessels in the lungs.
The study of the effects of the ambrisentan and tadalafil drugs,
carried out in collaboration with Gilead Sciences Inc. (GILD),
showed that the combination therapy worked better than either drug
administered on its own.
"The length of time before patients experienced clinical failure
was significantly prolonged for those receiving first-line
combination compared to monotherapy," GSK said.
The two companies now plan to seek regulatory approval for the
combination therapy by submitting the study data to regulators in
the U.S., European Union and elsewhere.
At 1309 GMT, GSK shares were down 24 pence or 1.66% at 1,424
pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires